Oculis Holding AG (NASDAQ:OCS) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its position in Oculis Holding AG (NASDAQ:OCS) by 12.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,744 shares of the company’s stock after purchasing an additional 1,800 shares during the period. Geode Capital Management LLC’s holdings in Oculis were worth $284,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, abrdn plc lifted its stake in Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company’s stock worth $17,150,000 after purchasing an additional 188,871 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Price Performance

OCS stock opened at $18.87 on Friday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $823.90 million, a P/E ratio of -9.78 and a beta of 0.19. The business has a 50 day simple moving average of $18.13 and a 200-day simple moving average of $18.26. Oculis Holding AG has a twelve month low of $10.79 and a twelve month high of $23.08.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, equities analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on OCS shares. Robert W. Baird increased their price target on shares of Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a research note on Thursday, March 13th. Chardan Capital reiterated a “buy” rating and set a $28.00 price target on shares of Oculis in a research note on Thursday, April 17th. Finally, HC Wainwright boosted their price target on shares of Oculis from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, April 17th.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.